Naltrexone and Bupropion for Methamphetamine Cravings
Yes, the combination of naltrexone and bupropion (Wellbutrin) does decrease cravings for methamphetamine, with reduction in craving mediating approximately 45-56% of the treatment effect on drug use. 1
Evidence for Craving Reduction
The most recent and highest-quality evidence comes from the ADAPT-2 trial, a large randomized controlled trial that specifically examined this combination for methamphetamine use disorder. The naltrexone-bupropion combination significantly reduced methamphetamine cravings, and this craving reduction was the primary mechanism through which the medication worked - accounting for 56% of the treatment effect on self-reported use and 45% of the effect on drug screen-confirmed use. 1
Mechanism of Action
The combination works through dual pathways:
- Naltrexone (opioid antagonist) blocks auto-inhibitory effects of β-endorphin on anorexigenic neurons, enhancing the weak effects of bupropion alone 2
- Bupropion increases dopamine levels and inhibits dopamine/norepinephrine reuptake, modulating hedonic eating and reward pathways 2
This same mechanism that reduces food cravings in obesity (the FDA-approved indication) appears to translate to reducing methamphetamine cravings through modulation of dopaminergic reward circuits.
Clinical Evidence Specifics
Primary Outcomes
- Methamphetamine-negative urine samples: 11.4% with naltrexone-bupropion vs 5.7% with placebo 3
- Craving reduction: Consistently associated with lower likelihood of returning to methamphetamine use 4
- Laboratory studies show bupropion alone reduced "any drug effect" (p<0.02) and "high" ratings (p<0.02) after methamphetamine administration 5
Important Caveats
Higher baseline craving predicts poorer response: Individuals with very high craving levels at baseline showed consistently lower probability of achieving negative drug screens, though the naltrexone-bupropion combination maintained its effect through 6 weeks while placebo lost effectiveness 4. This means the medication works, but severe baseline craving remains a negative prognostic factor.
Impulsivity matters differently: Higher impulsivity was associated with lower probability of transitioning to negative drug screens, but impulsivity did NOT predict transitions back to positive screens the way craving did 4. Focus your assessment on craving severity rather than impulsivity alone.
Practical Implementation
Dosing (from FDA labels and guidelines)
- Naltrexone: 380 mg extended-release injection every 3 weeks 1
- Bupropion: 450 mg daily (titrate from 150 mg daily for 1 week, then increase weekly to target dose) 2, 6
Contraindications to Consider
- Avoid if: Patient requires opioid therapy (naltrexone will block opioid effects and precipitate withdrawal) 2
- Avoid if: History of seizures, eating disorders, or abrupt discontinuation of alcohol/benzodiazepines (bupropion lowers seizure threshold) 2, 6
- Avoid if: Uncontrolled hypertension 2
- Hold before procedures: Discontinue before any procedure requiring fentanyl or other opioids 2
Monitoring
- Assess response at 12 weeks: If patient hasn't achieved meaningful reduction in use, consider alternative strategies 2
- Monitor blood pressure (can increase transiently in first 8 weeks) 2
- Watch for neuropsychiatric effects, especially in patients under 24 years (black box warning for suicidal ideation with bupropion) 7, 6
Who Benefits Most
A machine learning analysis identified that certain baseline characteristics predict better response, with NTX-BUP-preferred patients showing response rates of 26% vs 16% overall 8. While the specific classification rule requires validation, this suggests treatment selection can be optimized - though the specific predictors weren't fully detailed in available evidence.
Critical Limitations
This is NOT a standalone treatment. The evidence base comes from trials that included behavioral interventions alongside medication. Contingency management (behavioral reinforcement) shows 40-60% increases in abstinence rates and remains the most robust single intervention 3. The medication augments but does not replace comprehensive treatment.
Effect sizes are modest: The absolute difference in negative drug screens (11.4% vs 5.7%) represents meaningful but not dramatic improvement 3. Set realistic expectations with patients.
No guideline specifically addresses methamphetamine use disorder pharmacotherapy - the evidence cited comes from obesity treatment guidelines [7-2] and substance use disorder guidelines that note no pharmacotherapy can be recommended for stimulant dependence in primary care 9. However, the ADAPT-2 trial data 10, 1, 4 provides the most recent evidence that this combination does work specifically for methamphetamine through craving reduction.